Suppr超能文献

在持续性哮喘患者中,沙美特罗反应不受β2 - 肾上腺素能受体基因型的影响。

Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma.

作者信息

Bleecker Eugene R, Yancey Steven W, Baitinger Leslie A, Edwards Lisa D, Klotsman Michael, Anderson Wayne H, Dorinsky Paul M

机构信息

Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.

出版信息

J Allergy Clin Immunol. 2006 Oct;118(4):809-16. doi: 10.1016/j.jaci.2006.06.036. Epub 2006 Aug 28.

Abstract

BACKGROUND

Recent studies suggest that there might be an association between albuterol use and worsening asthma in patients homozygous for arginine (Arg/Arg) at codon 16 of the beta-receptor. However, it is not known whether similar responses occur in Arg/Arg patients receiving long-acting beta2-agonists.

OBJECTIVE

We sought to evaluate the effects of variation in the beta2-adrenergic receptor gene (ADRB2) on clinical response to salmeterol administered with fluticasone propionate.

METHODS

Subjects (n = 183) currently receiving short-acting beta2-agonists were randomized to twice-daily therapy with salmeterol, 50 microg, administered with fluticasone propionate, 100 microg, in a single inhaler or daily therapy with montelukast for 12 weeks, followed by a 2- to 4-day run-out period.

RESULTS

There was sustained and significant improvement (P < .001) over baseline in all measures of asthma control in subjects receiving salmeterol, regardless of Arg16Gly genotype. Morning peak expiratory flow in subjects with the Arg/Arg genotype showed 89.0 +/- 16.1 L/min improvement over baseline compared with 93.7 +/- 12.7 L/min for Gly/Gly subjects and 92.5 +/- 11.9 L/min for Arg/Gly subjects. Pairwise changes were similar for Arg/Arg compared with Gly/Gly or Arg/Gly genotypes (estimated differences, 4.7 L/min and 3.5 L/min, respectively). Responses did not appear to be modified by haplotype pairs. During the run-out period, all subjects had predictable and similar decreases in measures of asthma control, with no differences between genotypes.

CONCLUSION

Response to salmeterol does not vary between ADRB2 genotypes after chronic dosing with an inhaled corticosteroid.

CLINICAL IMPLICATIONS

Analyses from this study indicate that genetic polymorphisms leading to Arg16Gly sequence changes within the beta2-adrenergic receptor do not affect patients' responses to recommended asthma therapy with salmeterol and fluticasone propionate.

摘要

背景

近期研究表明,对于β受体第16密码子为精氨酸纯合子(Arg/Arg)的患者,使用沙丁胺醇可能与哮喘病情恶化有关。然而,尚不清楚接受长效β2激动剂治疗的Arg/Arg患者是否会出现类似反应。

目的

我们试图评估β2肾上腺素能受体基因(ADRB2)变异对沙美特罗联合丙酸氟替卡松临床反应的影响。

方法

将目前正在接受短效β2激动剂治疗的183名受试者随机分为两组,一组每日两次吸入含有50微克沙美特罗和100微克丙酸氟替卡松的单一吸入器,另一组每日服用孟鲁司特,为期12周,随后有2至4天的洗脱期。

结果

无论Arg16Gly基因型如何,接受沙美特罗治疗的受试者在所有哮喘控制指标上均较基线有持续且显著的改善(P <.001)。Arg/Arg基因型受试者的早晨呼气峰值流速较基线提高了89.0±16.1升/分钟,Gly/Gly受试者为93.7±12.7升/分钟,Arg/Gly受试者为92.5±11.9升/分钟。Arg/Arg与Gly/Gly或Arg/Gly基因型的两两变化相似(估计差异分别为4.7升/分钟和3.5升/分钟)。反应似乎未因单倍型对而改变。在洗脱期,所有受试者的哮喘控制指标均出现可预测且相似的下降,各基因型之间无差异。

结论

吸入糖皮质激素长期给药后,ADRB2基因型之间对沙美特罗的反应无差异。

临床意义

本研究分析表明,导致β2肾上腺素能受体内Arg16Gly序列变化的基因多态性不影响患者对推荐的沙美特罗和丙酸氟替卡松哮喘治疗的反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验